1. 788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers. (10th December 2020) Authors: Naidoo, Jarushka; Schreck, Karisa; Fu, Wei; Hu, Chen; Connolly, Roisin; Santa-Maria, Cesar; Lipson, Evan; Holdhoff, Matthias; Forde, Patrick; Riemer, Joanne; Barnes, Amanda; Aygun, Nafi; Kleinberg, Lawrence; Redmond, Kristin; Douville, Christopher; Bettegowda, Chetan; Venkatesan, Arun; Grossman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A 27-year-old man with diplopia, fatiguable ptosis and rash: a rare presentation of angiocentric T cell lymphoma with lymphomatoid vasculitis. (11th January 2011) Authors: Lefter, Stela; Forde, Patrick; Nashat, Hebah; Moylan, Eugene; Yacoob, Yaseen Journal: BMJ case reports Issue: Volume 2011 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models. Issue 1 (December 2016) Authors: Campion, Ciorsdan; Soden, Declan; Forde, Patrick Journal: BMC cancer Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Characterization of 298 Patients with Lung Cancer HarboringMETExon 14 Skipping Alterations. Issue 9 (September 2016) Authors: Schrock, Alexa B.; Frampton, Garrett M.; Suh, James; Chalmers, Zachary R.; Rosenzweig, Mark; Erlich, Rachel L.; Halmos, Balazs; Goldman, Jonathan; Forde, Patrick; Leuenberger, Kurt; Peled, Nir; Kalemkerian, Gregory P.; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Ali, Siraj M.; Ou, ... Journal: Journal of thoracic oncology Issue: Volume 11:Issue 9(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350]. (March 2022) Authors: Friedlaender, Alex; Naidoo, Jarushka; Luigi Banna, Giuseppe; Metro, Giulio; Forde, Patrick; Addeo, Alfredo Journal: Cancer treatment reviews Issue: Volume 104(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816. (April 2023) Authors: Spicer, Jonathan; Wang, Changli; Tanaka, Fumihiro; Chen, Ke-Neng; Ito, Hiroyuki; Liberman, Moishe; Chen, Qixun; Girard, Nicolas; Lu, Shun; Provencio, Mariano; Mitsudomi, Tetsuya; Awad, Mark; Felip, Enriqueta; Swanson, Scott; Forde, Patrick; Cai, Junliang; Mahmood, Javed; Hu, Nan; Tran, Phuong; Br... Journal: Lung cancer Issue: Volume 178(2023)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?. Issue 3 (2022) Authors: McGuigan, Roisin; Forde, Patrick Journal: Immuno-oncology insights Issue: Volume 3:Issue 3(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Leptospirosis: a globally increasing zoonotic disease. (5th November 2010) Authors: Rock, Clare; Brady, Deirdre; Forde, Patrick; Lucey, Patricia; Horgan, Mary Journal: BMJ case reports Issue: Volume 2010 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Issue 2 (December 2015) Authors: Rizvi, Naiyer; Barlesi, Fabrice; Brahmer, Julie; Felip, Enriqueta; Forde, Patrick; Garassino, Marina; Goldberg, Sarah; Vansteenkiste, Johan; Jarkowski, Anthony; McIntosh, Stuart; Zhao, Luping; Antonia, Scott Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. (4th November 2015) Authors: Rizvi, Naiyer; Barlesi, Fabrice; Brahmer, Julie; Felip, Enriqueta; Forde, Patrick; Garassino, Marina; Goldberg, Sarah; Vansteenkiste, Johan; Jarkowski, Anthony; McIntosh, Stuart; Zhao, Luping; Antonia, Scott Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗